GO
Loading...

Pharmaceuticals

More

  • *Actavis launches $21 bln bond deal. *Exxon Mobil to sell $7 bln in debt. Pharmaceutical company Actavis Plc launched a $21 billion corporate bond deal, the second-largest on record according to Thomson Reuters unit IFR.

  • Cramer's Stop Trading: Goldman unkind to Mankind  Tuesday, 3 Mar 2015 | 9:54 AM ET

    CNBC's Jim Cramer explains why he is watching Mankind.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • March 2- Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  • NEW YORK, March 2- U.S. Pharmaceutical company Actavis on Monday was marketing bonds that are expected to total $22 billion, the second largest amount ever sold by a corporate borrower. "Corporate deals are weighing on the market, and we've heard of some allocation out of bonds into equities," said Sean Murphy, a Treasuries trader at Societe Generale in New York.

  • Biotech drugmaker Amgen Inc.' s blood cancer drug Kyprolis doubled the time it kept the disease from worsening, compared with rival drug Velcade, according to the company. Amgen, based in Thousand Oaks, California, on Sunday released interim results from its study. The Amgen- funded study, known by the acronym ENDEAVOR, included 929 patients who had relapsed after...

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Actavis' contraceptive device wins U.S. FDA approval Friday, 27 Feb 2015 | 8:10 AM ET

    Feb 27- The U.S. Food and Drug Administration said on Friday it approved a hormonal contraceptive device, providing American women another reversible contraceptive choice as effective as sterilization. Actavis Plc holds the commercial license to the device, the marketing application of which was submitted by non-profit pharmaceutical company...

  • Why antibiotics need innovation: Ezekiel Emanuel  Friday, 27 Feb 2015 | 7:18 AM ET

    We are losing the battle against bacteria, says Dr. Ezekiel Emanuel, University of Pennsylvania Medical Ethics Department, discussing the need to incentivize the development of new antibiotics.

  • Novavax reports 4Q loss Friday, 27 Feb 2015 | 5:13 AM ET

    GAITHERSBURG, Md. _ Novavax Inc. on Thursday reported a loss of $31.5 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 9 cents per share. Novavax shares have risen 57 percent since the beginning of the year.

  • TRENTON, N.J.— Drugmaker Bristol-Myers Squibb Co. said Thursday that an experimental combination of two hepatitis C drugs— its daclatasvir and Gilead Sciences Inc.' s blockbuster drug Sovaldi— cured hepatitis C in just 12 weeks in nearly all the patients, who also are infected with the HIV virus. David Wyles, an associate professor at University of...

  • O'Neill eyes up to $2 bln for fund to fight superbugs Thursday, 26 Feb 2015 | 12:18 PM ET

    LONDON, Feb 26- A global fund to speed development of new antibiotics to counter the growing threat of drug-resistant superbugs is likely to need up to $2 billion, the head of a review backed by the British government said on Thursday. Former Goldman Sachs chief economist Jim O'Neill has urged the establishment of an innovation fund to support research, arguing...

  • LAKE FOREST, Ill.— Shares of Akorn Inc. jumped Thursday after the generic-drug maker's fourth-quarter results and its outlook for 2015 surpassed Wall Street expectations. Akorn said its net income and revenue more than doubled after it acquired two other companies, Hi-Tech Pharmacal and VersaPharm, and had 14 drugs approved during the year.

  • Bayer R&D budget to increase  Thursday, 26 Feb 2015 | 6:00 AM ET

    Marijn Dekkers, CEO of Bayer, says the company plans to increase its R&D budget this year, after strong earnings.

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • *Sales of 5 key drugs seen at close to 4 bln eur in 2015. LEVERKUSEN, Germany, Feb 26- Germany's largest drugmaker Bayer said it expects underlying core earnings to increase by more than 10 percent this year, banking on a boost from new drugs such as stroke prevention pill Xarelto. The company is benefiting from a strong dollar in particular as North America accounts...

  • Feb 25- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported. Pharmacyclics could fetch $17 billion- $18 billion from a possible sale, Bloomberg said on Wednesday, citing people familiar with the matter. A Pharmacyclics official said the company does not comment on rumors or...

  • Feb 25- Cancer drugmaker Pharmacyclics Inc is exploring a possible sale of the company and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported, citing people familiar the matter. Pharmacyclics could fetch $17- $18 billion from a possible sale, Bloomberg said on Wednesday. Sales of Imbruvica, which got U.S. Food& Drug Administration...

  • The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson& Johnson and Merck& Co.. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant...